Clinical trial
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
NCT05972564
Study timeline
Study start (actual)2023-09-06Date precision: day
Registry last updated2026-09-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Obesityunresolved
Metabolic Syndromeunresolved
Interventions
Empagliflozin 25 MGDRUG · verified · RxNorm: empagliflozin 25 MG
PlaceboDRUG
Sponsors & collaborators
Vanderbilt University Medical Centerlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05972564 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.